Joonas H Kauppila
Overview
Explore the profile of Joonas H Kauppila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
2176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Putila E, Helminen O, Helmio M, Huhta H, Jalkanen A, Kallio R, et al.
Ann Surg Oncol
. 2023 Dec;
31(4):2689-2698.
PMID: 38153640
Background: To date, no large population-based studies have compared complications and short-term outcomes between neoadjuvant chemotherapy and upfront surgery in gastric cancer. More nationwide studies with standardized reporting on complications...
22.
Putila E, Helminen O, Helmio M, Huhta H, Jalkanen A, Kallio R, et al.
BJS Open
. 2023 Oct;
7(5).
PMID: 37864576
Background: The incidence of postoperative complications after gastrectomy for gastric cancer is not well known. More population-based studies using established complication classifications are needed for international comparison. The aim of...
23.
Eskuri M, Kemi N, Helminen O, Huhta H, Kauppila J
Virchows Arch
. 2023 Sep;
485(4):655-664.
PMID: 37750927
Toll-like receptors (TLRs) are expressed on both immune cells and tumor cells, triggering both anti-tumor and pro-tumor responses. Therefore, TLRs have potential as prognostic biomarkers and immunotherapeutic targets. The aim...
24.
Holmberg D, Santoni G, von Euler-Chelpin M, Farkkila M, Kauppila J, Maret-Ouda J, et al.
BMJ
. 2023 Sep;
382:e076017.
PMID: 37704252
Objective: To assess the incidence rate of oesophageal adenocarcinoma among patients with non-erosive gastro-oesophageal reflux disease compared with the general population. Design: Population based cohort study. Setting: All patients in...
25.
Akerstrom J, Santoni G, von Euler Chelpin M, Ness-Jensen E, Kauppila J, Holmberg D, et al.
Gastroenterology
. 2023 Sep;
166(1):132-138.e3.
PMID: 37690771
Background & Aims: Antireflux treatment is recommended to reduce esophageal adenocarcinoma in patients with Barrett's esophagus. Antireflux surgery (fundoplication) counteracts gastroesophageal reflux of all types of carcinogenic gastric content and...
26.
Cunha A, Compton K, Xu R, Mishra R, Drangsholt M, Antunes J, et al.
JAMA Oncol
. 2023 Sep;
9(10):1401-1416.
PMID: 37676656
Importance: Lip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning....
27.
Martos O, Hoque M, Keskinarkaus A, Kemi N, Napankangas J, Eskuri M, et al.
Pathol Res Pract
. 2023 Jul;
248:154694.
PMID: 37494804
Histological analysis with microscopy is the gold standard to diagnose and stage cancer, where slides or whole slide images are analyzed for cell morphological and spatial features by pathologists. The...
28.
Akerstrom J, Santoni G, von Euler Chelpin M, Chidambaram S, Markar S, Maret-Ouda J, et al.
Ann Surg
. 2023 Jul;
278(6):904-909.
PMID: 37450697
Objective: The objective of this study was to test the hypothesis that bariatric surgery decreases the risk of esophageal and cardia adenocarcinoma. Background: Obesity is strongly associated with esophageal adenocarcinoma...
29.
Wani S, Holmberg D, Santoni G, Kauppila J, Farkkila M, von Euler-Chelpin M, et al.
Gastroenterology
. 2023 Jun;
165(4):909-919.e13.
PMID: 37279832
Background & Aims: Post-endoscopy esophageal adenocarcinoma (PEEC) and post-endoscopy esophageal neoplasia (PEEN) undermine early cancer detection in Barrett's esophagus (BE). We aimed to assess the magnitude and conduct time-trend analysis...
30.
Kauppila J, Markar S, Santoni G, Holmberg D, Lagergren J
JAMA Surg
. 2023 May;
158(8):817-823.
PMID: 37223939
Importance: Bariatric surgery can resolve hyperlipidemia, cardiovascular disease, and diabetes, but the long-term postoperative trajectories of medications for these conditions are unknown. Objective: To clarify the long-term use of lipid-lowering,...